EF Hutton Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Anavex Life Sciences Corp. -3.86%

Anavex Life Sciences Corp.

AVXL

3.98

-3.86%

EF Hutton analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ: AVXL) with a Buy and maintains $46 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via